ID

19883

Descrição

The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. Documentation process: This form is to be obtained in Screening #1, Screening #2, Screening #3, Baseline week 0, week 12, week 24, week 36, week 48, week 60, week 72, week 84, week 96, week 108, week 120, week 128 and Premature Study Withdrawl. Perform evaluations in the following order: Timed 25-Foot Walk Test, Dominant Hand Nine Hole Peg Test, Non-Dominant Hand Nine Hole Peg Test and PASAT. The first and second performance of any given evaluation must be completed before one of the other evaluations in conducted.

Palavras-chave

Versões (1)

1. 30/01/2017 30/01/2017 -

Transferido a

30 de janeiro de 2017

DOI

Para um pedido faça login.

Licença